Drugs / Sodium Hyaluronate
Sodium Hyaluronate
also known as
hyaluronate · Hyalein · Hyalgan · hyaluronic acid · Hylocomod · ADANT · EUFLEXXA · Fermathron · +20 more
Trials 60
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 02 trials | ||||||
| Phase 0 | NCT07665619 | Jul 2026 → Dec 2027 expected | radiation cystitis | Fujian Medical University Union Hospital | Not yet recruiting | No outcome recorded |
| Phase 0 | NCT04142411 | Nov 2019 → May 2020 | carpal tunnel syndrome | Assiut University | Unknown | No outcome recorded |
| Phase 13 trials | ||||||
| Phase 1 | NCT04081610 | Sep → Oct 2019 | dry eye syndrome | Laboratorios Sophia S.A de C.V. | Completed | No outcome recorded |
| Phase 1 | NCT03697876 | Aug 2018 → Jun 2024 | dry eye syndrome | Laboratorios Sophia S.A de C.V. | Completed | No outcome recorded |
| Phase 1 | NCT03180125 | Aug → Oct 2017 | carpal tunnel syndrome | Assiut University | Completed | No outcome recorded |
| Phase 1/21 trial | ||||||
| Phase 1/2 | NCT07688096 | Jan → Dec 2027 expected | Ehlers-Danlos syndrome, hypermobility type, chronic pain syndrome, hypermobility spectrum disorder, hypermobility syndrome | Manhattan Pain Medicine, PLLC | Not yet recruiting | No outcome recorded |
| Phase 28 trials | ||||||
| Phase 2 | NCT07413172 | Jul 2026 → Jul 2028 expected | dry eye syndrome | University of Miami | Not yet recruiting | No outcome recorded |
| Phase 2 | NCT06851364 | Oct 2022 → Feb 2023 | dry eye syndrome | International Islamic University Malaysia | Completed | No outcome recorded |
| Phase 2 | NCT04704531 | Jan → Jun 2022 | dry eye syndrome | Laboratorios Sophia S.A de C.V. | Completed | No outcome recorded |
| Phase 2 | NCT02810119 | Nov 2016 → Oct 2017 | conjunctivochalasis | Ocuwize LTD | Completed | No outcome recorded |
| Phase 2 | NCT04569656 | Feb → Dec 2016 | Parkinson disease | IRCCS San Raffaele Roma | Completed | No outcome recorded |
| Phase 2 | NCT02493712 | Jan 2016 → Jul 2018 | ulcerative colitis | Holy Stone Healthcare Co., Ltd | Completed | No outcome recorded |
| Phase 2 | NCT01267214 | Feb 2009 → Feb 2010 | osteoarthritis, knee | TRB Chemedica | Completed | No outcome recorded |
| Phase 2 | NCT00918736 | Oct 2007 → Oct 2008 | osteoarthritis | Kaohsiung Veterans General Hospital. | Completed | No outcome recorded |
| Phase 2/32 trials | ||||||
| Phase 2/3 | NCT07337863 | Aug → Sep 2026 overdue | osteoarthritis, knee | Universitas Sriwijaya | Not yet recruiting | No outcome recorded |
| Phase 2/3 | NCT06999993 | Jun 2025 → May 2026 overdue | — | Misr University for Science and Technology | Active not recruiting | No outcome recorded |
| Phase 313 trials · 2 missed | ||||||
| Phase 3 | NCT07819461 | Sep 2026 → Jun 2027 expected | osteoarthritis, knee | IBSA Institut Biochimique SA | Not yet recruiting | No outcome recorded |
| Phase 3 | NCT06803654 | May → Jun 2025 | ocular hyperemia | Bausch & Lomb Incorporated | Completed | No outcome recorded |
| Phase 3 | NCT06684626 | Mar → Jul 2024 | chronic prostatitis | Federico II University | Completed | No outcome recorded |
| Phase 3 | NCT06461975 | Jan → Apr 2023 | retinopathy of prematurity | Alexandria University | Completed | No outcome recorded |
| Phase 3 | NCT04711642 | Jan 2021 → Jan 2022 | cataract, dry eye syndrome | Fundación Oftalmológica Los Andes | Unknown | No outcome recorded |
| Phase 3 | NCT03515187 | Jun 2018 → Apr 2021 | dry eye syndrome | Shenzhen Hospital of Southern Medical University | Unknown | No outcome recorded |
| Phase 3 | NCT02258295 | Jan 2017 → Sep 2019 | epicondylitis | Shaare Zedek Medical Center | Completed | No outcome recorded |
| Phase 3 | NCT03000556 | Sep 2016 → Dec 2018 | corneal disorder | Fang Duan | Unknown | Missed primary |
| Phase 3 | NCT01382225 | Jul 2011 → May 2012 | dry eye syndrome | Alcon Research | Completed | No outcome recorded |
| Phase 3 | NCT00750724 | Jul 2008 → Sep 2009 | osteoarthritis | Khon Kaen University | Completed | No outcome recorded |
| Phase 3 | NCT00599716 | Dec 2006 → Apr 2008 | dry eye syndrome | Lantibio | Completed | No outcome recorded |
| Phase 3 | NCT00330135 | Jan 2005 → Mar 2007 | osteoarthritis, hip | Daiichi Sankyo | Terminated | Missed primary |
| Phase 3 | NCT00377624 | Jan 2002 → Sep 2004 | osteoarthritis | Sanofi | Completed | No outcome recorded |
| Phase 411 trials · 1 missed | ||||||
| Phase 4 | NCT07280442 | Jan → Dec 2026 expected | lichen planus, oral | Universidad Complutense de Madrid | Not yet recruiting | No outcome recorded |
| Phase 4 | NCT07308015 | Jun 2025 → Jun 2026 overdue | rhinitis | China-Japan Union Hospital | Recruiting | No outcome recorded |
| Phase 4 | NCT06860659 | Sep 2024 → May 2025 overdue | dry eye syndrome | Department of Medical Services Ministry of Public Health of Thailand | Enrolling by invitation | No outcome recorded |
| Phase 4 | NCT05591651 | Jan 2023 → Dec 2025 overdue | — | Specijalisticka Pedijatrijska Ordinacija prim.mr.sc. Maja Stimac, Specijalist Pedijatrije Sspecijalnosti Neonatologije | Recruiting | No outcome recorded |
| Phase 4 | NCT04441528 | Nov 2018 → Nov 2019 | blepharitis | Istanbul University - Cerrahpasa | Completed | No outcome recorded |
| Phase 4 | NCT03319420 | Mar 2018 → Jan 2021 | dry eye syndrome | Ocuwize LTD | Completed | No outcome recorded |
| Phase 4 | NCT02826031 | Apr 2016 → Oct 2017 | osteoarthritis, knee | Kunming Baker Norton Pharmaceutical Sales Co., Ltd. | Unknown | No outcome recorded |
| Phase 4 | NCT02595606 | Sep 2015 → Mar 2016 | diabetes mellitus, dry eye syndrome | Sun Yat-sen University | Unknown | No outcome recorded |
| Phase 4 | NCT00422643 | Mar → Oct 2007 | osteoarthritis, knee | Assaf-Harofeh Medical Center | Unknown | No outcome recorded |
| Phase 4 | NCT00144820 | May 1999 → Nov 2001 | osteoarthritis, knee | Glostrup University Hospital, Copenhagen | Unknown | Missed primary |
| Phase 4 | NCT00493662 | — | dry eye syndrome | Innovative Medical | Completed | No outcome recorded |
| Phase not applicable20 trials | ||||||
| — | NCT07524725 | Jan 2027 → Dec 2032 expected | dry eye syndrome | Zhongshan Ophthalmic Center, Sun Yat-sen University | Not yet recruiting | No outcome recorded |
| — | NCT07853196 | Mar → Jul 2026 | — | Cyprus Health and Social Sciences University | Completed | No outcome recorded |
| — | NCT07835373 | Aug 2025 → Jun 2026 | impacted teeth, multiple | Inonu University | Completed | No outcome recorded |
| — | NCT07097922 | Aug 2025 → May 2026 overdue | dry eye syndrome | He Eye Hospital | Not yet recruiting | No outcome recorded |
| — | NCT06656403 | Oct → Nov 2024 overdue | dry eye syndrome | He Eye Hospital | Not yet recruiting | No outcome recorded |
| — | NCT07412535 | Mar → Oct 2024 | — | Mansoura University | Completed | No outcome recorded |
| — | NCT06082531 | Sep 2023 → Dec 2025 overdue | articular cartilage disorder, osteoarthritis, knee | Xijing Hospital | Recruiting | No outcome recorded |
| — | NCT06798025 | Jul 2023 → Jun 2024 | stenosis of lacrimal punctum | Tanta University | Completed | No outcome recorded |
| — | NCT07066527 | Jun 2022 → Dec 2025 overdue | vascular malformation | Qilu Hospital of Shandong University | Recruiting | No outcome recorded |
| — | NCT05032924 | Aug 2021 → Jul 2024 | rotator cuff syndrome | Chang Gung Memorial Hospital | Unknown | No outcome recorded |
| — | NCT04681937 | Jun → Nov 2021 | rotator cuff syndrome | Bezmialem Vakif University | Unknown | No outcome recorded |
| — | NCT04667819 | Dec 2020 → Dec 2021 | dry eye syndrome | Tianjin Eye Hospital | Unknown | No outcome recorded |
| — | NCT04668131 | Sep 2020 → Mar 2022 | dry eye syndrome | Peking University Third Hospital | Completed | No outcome recorded |
| — | NCT04000789 | Jul → Dec 2019 | dry eye syndrome, proliferative diabetic retinopathy | Dr Cipto Mangunkusumo General Hospital | Unknown | No outcome recorded |
| — | NCT03365388 | Apr 2018 → Apr 2020 | periarthritis | Peking University People's Hospital | Unknown | No outcome recorded |
| — | NCT01284439 | Jan 2011 → Jan 2012 | eye adnexa disorder, glaucoma | Mahidol University | Unknown | No outcome recorded |
| — | NCT01101984 | Feb 2010 → Apr 2012 | dry eye syndrome | Santen Pharmaceutical Co., Ltd. | Completed | No outcome recorded |
| — | NCT00969501 | Aug 2009 → Aug 2010 | osteoarthritis | Georgia Institute for Clinical Research, LLC | Completed | No outcome recorded |
| — | NCT00570648 | Jun 2007 → Jun 2008 | corneal disorder | University of Virginia | Completed | No outcome recorded |
| — | NCT01363414 | Jan 2007 → Jun 2010 | dry eye syndrome | Ramathibodi Hospital | Completed | No outcome recorded |
| Comparator or background therapy57 trials | ||||||
| Phase 0 | NCT05018481 Comparator | Sep 2022 → Oct 2028 expected | alcoholic hepatitis | The Cleveland Clinic | Recruiting | No outcome recorded |
| Phase 0 | NCT05025865 Comparator | Feb 2022 → Oct 2028 expected | — | The Cleveland Clinic | Recruiting | No outcome recorded |
| Phase 0 | NCT04130100 Comparator | Apr 2019 → Sep 2021 | osteoarthritis, knee | CAR-T (Shanghai) Biotechnology Co., Ltd. | Unknown | No outcome recorded |
| Phase 1 | NCT06370585 Comparator | May → Jul 2024 | dry eye syndrome | Laboratorios Sophia S.A de C.V. | Completed | No outcome recorded |
| Phase 1 | NCT05618730 Background | Sep 2022 → Dec 2023 | dry eye syndrome | Eximore Ltd. | Unknown | No outcome recorded |
| Phase 1/2 | NCT03955497 Comparator | Oct 2018 → Oct 2022 | chondromalacia, osteoarthritis, knee | Qilu Hospital of Shandong University | Unknown | No outcome recorded |
| Phase 2 | NCT07852234 Background | Sep 2026 → Oct 2027 expected | Sjogren syndrome | Beijing Tongren Hospital | Not yet recruiting | No outcome recorded |
| Phase 2 | NCT06614348 Comparator | Oct 2024 → Jun 2025 overdue | cataract 50 with or without glaucoma, senile cataract | Shanghai General Hospital, Shanghai Jiao Tong University School of Medicine | Not yet recruiting | No outcome recorded |
| Phase 2 | NCT06798727 Comparator | Mar 2023 → Mar 2027 expected | osteoarthritis, knee | Medipost Co Ltd. | Active not recruiting | No outcome recorded |
| Phase 2 | NCT06146881 Comparator | Oct 2022 → Dec 2023 | dry eye syndrome | Indonesia University | Unknown | No outcome recorded |
| Phase 2 | NCT05429229 Comparator | Nov 2021 → Dec 2023 | diabetic retinopathy, disorder of defective peroxisome oxidative status, dry eye syndrome | Adolfo Daniel Rodriguez-Carrizalez | Unknown | No outcome recorded |
| Phase 2 | NCT03028428 Comparator | Dec 2016 → Dec 2018 | osteoarthritis, knee | Affiliated Hospital of Jiangsu University | Unknown | No outcome recorded |
| Phase 2 | NCT02855073 Comparator | Jul 2014 → Dec 2019 | articular cartilage disorder, osteoarthritis, knee | Shanghai AbelZeta Ltd. | Unknown | No outcome recorded |
| Phase 2 | NCT02162693 Comparator | Nov 2013 → May 2016 | osteoarthritis, knee | Shanghai AbelZeta Ltd. | Completed | No outcome recorded |
| Phase 2 | NCT01493180 Comparator | Dec 2011 → Nov 2012 | keratoconjunctivitis | Otsuka Pharmaceutical Co., Ltd. | Completed | Missed primary |
| Phase 2 | NCT01135511 Comparator | Jul 2010 → Apr 2011 | dry eye syndrome | Pfizer | Completed | No outcome recorded |
| Phase 2 | NCT00760045 Comparator | Aug → Oct 2008 | dry eye syndrome | Alcon Research | Completed | No outcome recorded |
| Phase 2/3 | NCT07812129 Comparator | Nov 2023 → May 2025 | — | Cairo University | Completed | No outcome recorded |
| Phase 2/3 | NCT05912946 Comparator | Oct 2023 → Oct 2024 | interstitial cystitis | West China Hospital | Unknown | Met primary |
| Phase 2/3 | NCT01735058 Comparator | Feb → Dec 2012 | shoulder impingement syndrome | Isfahan University of Medical Sciences | Unknown | No outcome recorded |
| Phase 3 | NCT06570291 Comparator | Feb 2025 → Dec 2026 expected | osteoarthritis, knee | Wuxi Cellular Biopharmaceutical Group Ltd. | Recruiting | No outcome recorded |
| Phase 3 | NCT02777723 Comparator | May → Jul 2016 | dry eye syndrome | Chong Kun Dang Pharmaceutical | Unknown | No outcome recorded |
| Phase 3 | NCT01510535 Comparator | Dec 2011 → Mar 2012 | osteoarthritis, knee | LG Life Sciences | Completed | Met primary |
| Phase 3 | NCT00885079 Comparator | May 2009 → Mar 2010 | dry eye syndrome | Otsuka Pharmaceutical Co., Ltd. | Completed | No outcome recorded |
| Phase 3 | NCT01240382 Comparator | ? → Feb 2008 | dry eye syndrome | Santen Pharmaceutical Co., Ltd. | Completed | Met primary |
| Phase 4 | NCT07679685 Comparator | Jun 2026 → Feb 2027 expected | dry eye syndrome | Beijing Tongren Hospital | Not yet recruiting | No outcome recorded |
| Phase 4 | NCT07405840 Comparator | Jun 2025 → Aug 2026 overdue | osteoarthritis | Clinical Center of Vojvodina | Active not recruiting | No outcome recorded |
| Phase 4 | NCT06279507 Comparator | Feb 2024 → Jan 2025 | osteoarthritis, knee | Phramongkutklao College of Medicine and Hospital | Unknown | No outcome recorded |
| Phase 4 | NCT05603468 Comparator | Dec 2022 → Dec 2026 expected | disease of the tendon | Second Affiliated Hospital, School of Medicine, Zhejiang University | Active not recruiting | No outcome recorded |
| Phase 4 | NCT04704518 Comparator | Sep 2022 → Dec 2023 | — | Laboratorios Sophia S.A de C.V. | Completed | No outcome recorded |
| Phase 4 | NCT04702776 Comparator | Dec 2021 → May 2023 | dry eye syndrome | Laboratorios Sophia S.A de C.V. | Completed | No outcome recorded |
| Phase 4 | NCT05771194 Comparator | Feb 2021 → Mar 2022 | eyelid disorder | Tianjin Medical University Eye Hospital | Completed | No outcome recorded |
| Phase 4 | NCT04557943 Comparator | Sep 2019 → Apr 2020 | osteoarthritis, knee | Hasanuddin University | Completed | No outcome recorded |
| Phase 4 | NCT02640144 Comparator | Feb 2017 → Feb 2018 | articular cartilage disorder | Ziv Medical Center | Unknown | No outcome recorded |
| Phase 4 | NCT02323451 Comparator | Dec 2014 → Aug 2016 | osteoarthritis, knee | Shanghai Qisheng Biological Preparation Co., Ltd. | Unknown | No outcome recorded |
| Phase 4 | NCT02117687 Comparator | May 2014 → Jan 2015 | dry eye syndrome | Allergan | Completed | No outcome recorded |
| Phase 4 | NCT00987727 Comparator | Nov 2009 → Jul 2010 | dry eye syndrome | Allergan | Completed | No outcome recorded |
| Phase 4 | NCT00938704 Comparator | Jun 2009 | dry eye syndrome | Allergan | Completed | No outcome recorded |
| Phase 4 | NCT00761202 Comparator | Aug 2007 → Jun 2008 | dry eye syndrome | Allergan | Completed | No outcome recorded |
| — | NCT07536971 Comparator | May 2026 → Dec 2028 expected | adhesions of uterus | Beijing Obstetrics and Gynecology Hospital | Not yet recruiting | No outcome recorded |
| — | NCT06818487 Background | Jul 2025 → Jan 2027 expected | dry eye syndrome | Beijing Tongren Hospital | Not yet recruiting | No outcome recorded |
| — | NCT06981104 Comparator | Nov 2024 → Feb 2025 | asthenopia, dry eye syndrome | Second Affiliated Hospital, School of Medicine, Zhejiang University | Completed | No outcome recorded |
| — | NCT06576245 Background | Sep 2023 → Feb 2024 | dry eye syndrome | University of Seville | Completed | No outcome recorded |
| — | NCT05861570 Comparator | May 2023 → Apr 2024 | frozen shoulder | Taipei Veterans General Hospital, Taiwan | Unknown | No outcome recorded |
| — | NCT07033312 Comparator | Apr 2023 → Feb 2025 | osteoarthritis, knee | Taichung Veterans General Hospital | Completed | No outcome recorded |
| — | NCT04980144 Comparator | Mar → Aug 2023 | — | He Eye Hospital | Unknown | No outcome recorded |
| — | NCT05682547 Comparator | Dec 2022 → Jun 2023 | — | He Eye Hospital | Completed | No outcome recorded |
| — | NCT05257213 Comparator | Feb 2022 → Feb 2026 overdue | adhesions of uterus | Nadezhda Women's Health Hospital | Recruiting | No outcome recorded |
| — | NCT05130814 Background | Dec 2021 → Mar 2024 | decubitus ulcer | Emoled | Completed | No outcome recorded |
| — | NCT06696625 Background | Jul 2021 → Nov 2025 overdue | dry eye syndrome | Beijing Tongren Hospital | Recruiting | No outcome recorded |
| — | NCT04421300 Comparator | Jul 2020 → Apr 2021 | dry eye syndrome | Zhongshan Ophthalmic Center, Sun Yat-sen University | Completed | No outcome recorded |
| — | NCT05385562 Comparator | Jan 2020 → May 2022 | macular retinal edema | Al-Azhar University | Completed | No outcome recorded |
| — | NCT03705949 Comparator | Sep 2017 → Sep 2018 | cataract | Democritus University of Thrace | Completed | No outcome recorded |
| — | NCT03640351 Comparator | Aug 2017 → Feb 2019 | cataract, dry eye syndrome | Yonsei University | Completed | No outcome recorded |
| — | NCT03116776 Comparator | May 2017 → Jul 2018 | dry eye syndrome | Guang'anmen Hospital of China Academy of Chinese Medical Sciences | Unknown | No outcome recorded |
| — | NCT02608489 Comparator | Jan 2014 → Jan 2015 | dry eye syndrome | Soonchunhyang University Hospital | Completed | No outcome recorded |
| — | NCT02147509 Background | Mar 2013 → Apr 2014 | Sjogren syndrome | Jinyang Li | Completed | No outcome recorded |
News releases announcing trial results or a regulatory action · 7
| Date | Issuer | Release |
|---|---|---|
| 2026-09-28 | Bausch Health Americas, Inc. | Results Bausch + Lomb to Present 28 Scientific Studies at Academy 2026 Anaheim bausch.com ↗
Studies highlighted rapid and durable redness relief with a novel formulation of LUMIFY® redness reliever eye drops containing hyaluronic acid |
| 2025-02-24 | IBSA Institut Biochimique SA | Results 10 years of Nahyco® technology celebrated at IMCAS 2025 ibsagroup.com ↗
Among these, Dr S. Liew presented clinical evidence highlighting the regenerative properties of hybrid cooperative complexes of hyaluronic acid: HCC treatment showed promising results in tissue repair, demonstrating a potential role in regenerative medicine 2 . |
| 2021-06-29 | Galderma R&D | Regulatory Galderma receives FDA approval for Restylane® Contour for cheek augmentation and correction of midface contour deficiencies galderma.com ↗
Galderma announced today the U.S. Food and Drug Administration (FDA) has approved Restylane® Contour for cheek augmentation and correction of midface contour deficiencies in adults over the age of 21. |
| 2019-07-01 | Teva Branded Pharmaceutical Products R&D, Inc. | Regulatory Teva Announces Launch of 1% Sodium Hyaluronate in the United States tevapharm.com ↗
The product received approval from the Center for Devices and Radiological Health of the U.S. Food and Drug Administration. |
| 2015-12-25 | Seikagaku Corporation | Regulatory Seikagaku Announces U.S. FDA Approval for VISCO-3, a Joint Function Improving Agent Supplied as a Three-Injection Kit seikagaku.co.jp ↗
Seikagaku Corporation (Tokyo) today announced that U.S. Food and Drug Administration (FDA) approval was obtained for VISCO-3™, a medical device indicated for knee osteoarthritis, on December 21, 2015 (U.S. local time). |
| 2011-03-24 | Seikagaku Corporation | Regulatory Seikagaku announces U.S. FDA approval of Gel-One, a single injection Hyaluronic Acid injectable treatment for osteoarthritis pain of the knee. seikagaku.co.jp ↗
today announced that the U.S. Food and Drug Administration (FDA) approved Gel-One® (development code: Gel-200), a medical device for the treatment of pain in osteoarthritis of the knee, on March 22, 2011 (U.S. local time) |
| 2009-09-28 | Seikagaku Corporation | Regulatory The application of SUPARTZ® was submitted to FDA for additional indication of treatment of pain associated with shoulder osteoarthritis seikagaku.co.jp ↗
The application of SUPARTZ® was submitted to FDA for additional indication of treatment of pain associated with shoulder osteoarthritis |
All press releases naming this drug 10 releases
Evidence & citations 31 cited values
Every value below carries the sentence it was read from. 120 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | sodium hyaluronate | “Patients were treated with a combination of punctal dilation and topical medication in the form of preservative-free steroid eye drops based on dexamethasone sodium phosphate...” NCT06798025 ↗108“After the screening visits, eligible patients will be randomized to 1 of 3 study groups: (1) IBD98 M 0.8 g/day (mesalamine 0.8 g with sodium hyaluronate 92 mg), (2) IBD98 M 1.2...” NCT02493712 ↗ “Participants will receive a single intra-articular injection of high-molecular-weight hyaluronic acid (Reviscon Re-Cross, MV Pharm; 88 mg sodium hyaluronate \[2.2%\] in 4 mL...” NCT07405840 ↗ “arm1: sodium hyaluronate (4ml) arm2: platelet-rich-plasma (4ml) arm3: methylprednisolone acetate (1ml methylprednisolone acetate + 3 ml serum saline) arm4: serum saline (4ml)” NCT04681937 ↗ “given 0.1% sodium hyaluronate eye drops 4 times daily for 3 days before surgery (Jiang Xi, Zhen Shiming Pharmaceutical Co., Ltd.) and 3 months after surgery” NCT05771194 ↗ “The background treatment includes: (1) hydroxychloroquine, 400 mg/day; (2) methylprednisolone, 8 mg/day; and (3) sodium hyaluronate eye drops, 4 times/day.” NCT07852234 ↗ “The association with sodium hyaluronate (low molecular weight depolymerizes) rapidly attracting water and amplifying the desired clinical effect.” NCT04569656 ↗ “Monovisc® (Anika Therapeutics, Inc., Bedford, MA, USA), containing 22 mg/mL cross-linked, high-molecular-weight sodium hyaluronate, was used.” NCT07853196 ↗ “It consists of a preservative-free eye drop composed of sodium hyaluronate 0.4%, one drop is applied in each eye every 4 hours for a month.” NCT05429229 ↗ “Three Injections of EUFLEXXA (Sodium Hyaluronate) for Treatment of Chronic Shoulder Pain Associated With Osteoarthritis (OA)” NCT00969501 ↗ “1mL prednisone (MSD) + 2mL sodium hyaluronate (biochemical Industry Co., Ltd.) was injected under arthroscopy” NCT05603468 ↗ |
| Known as | ADANT | “To demonstrate the difference in terms of symptomatic efficacy between ADANT® sodium hyaluronate and placebo following an intra-articular injection” NCT00330135 ↗ |
| Known as | EUFLEXXA | “Three Injections of EUFLEXXA (Sodium Hyaluronate) for Treatment of Chronic Shoulder Pain Associated With Osteoarthritis (OA)” NCT00969501 ↗ |
| Known as | Fermathron | “Ultrasound guided injection of sodium hyaluronate; Fermathron ™, 20 mg/2ml of Sodium Hyaluronate, 3 weekly injections.” NCT01735058 ↗ |
| Known as | Hialid | “0.1% sodium hyaluronate eye drops (Hialid®)” NCT07679685 ↗ |
| Known as | High Hyal Plus | “A single knee administration of High Hyal Plus Inj.(1% Sodium Hyaluronate 20mg/2ml)” NCT06798727 ↗ |
| Known as | High Hyal Plus Inj. | “A single knee administration of High Hyal Plus Inj.(1% Sodium Hyaluronate 20mg/2ml)” NCT06798727 ↗ |
| Known as | HL-01 | “A Phase 3, Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Efficacy and Safety of a Single Intra-Articular Injection of a Solution of High and Low Molecular...” NCT07819461 ↗ |
| Known as | Hyabak | “Preservative-free, 0.15% sodium hyaluronate (Hyabak, Théa laboratories) 4 times daily.” NCT05618730 ↗ |
| Known as | HYAJOINT Synovial Fluid Supplement | “HYAJOINT Synovial Fluid Supplement, active ingredient: Sodium Hyaluronate 25 mg, package: 2.5 mL per syringe” NCT05032924 ↗ |
| Known as | Hyalein | “sodium hyaluronate (Hyalein) once weekly for 4 consecutive weeks” NCT07665619 ↗ |
| Known as | Hyalgan | “2 ml sodium hyaluronate (Hyalgan) into the ankle joints.” NCT00918736 ↗2“sodium hyaluronate 2 mL (Hyalgan 10.3 mg/mL)” PMID 18415773 ↗ Mar 2008 “Sodium Hyaluronate (Hyalgan)” NCT01267214 ↗ |
| Known as | hyaluronan | “2 ml sodium hyaluronate (hyaluronan)” NCT00144820 ↗ |
| Known as | hyaluronate | “This study will investigate the effectiveness of hyaluronate in treatment of chronic LE.” NCT02258295 ↗ |
| Known as | hyaluronic acid | “Participants will receive a single intra-articular injection of high-molecular-weight hyaluronic acid (Reviscon Re-Cross, MV Pharm; 88 mg sodium hyaluronate \[2.2%\] in 4 mL...” NCT07405840 ↗2“A single knee administration of Hyaluronic acid(1% Sodium Hyaluronate 20mg/2ml)” NCT06798727 ↗ “Sodium hyaluronate (hyaluronic acid)” NCT00422643 ↗ |
| Known as | hyaluronic acid sodium salt | ClinicalTrials.gov intervention name — accepted as the source's own label NCT05130814 ↗ |
| Known as | HYLO COMOD eye drops | “Participants received 0.1% sodium hyaluronate eye drop (HYLO COMOD® eye drops, Ursapharm, Ltd., Germany).” NCT06696625 ↗ |
| Known as | Hylocomod | “The intervention arms will include two commercially available sodium hyaluronate 0.1% (Systane ultra plus and Hylo-comod)” NCT04711642 ↗1“0.1 % sodium hyaluronate (Hylocomod) quid for 6 weeks” NCT03705949 ↗ |
| Known as | Hylogel | “0.2 % sodium hyaluronate (Hylogel, Pharmex, Greece) quid for 6 weeks” NCT03705949 ↗ |
| Known as | Hyruan One | “(Sodium Hyaluronate (Hyruan One , LG)” NCT05861570 ↗ |
| Known as | Hyruan Plus | ClinicalTrials.gov intervention name — accepted as the source's own label NCT01510535 ↗ |
| Known as | Hyruan Plus Inj. | “Hyruan Plus Inj. (2ml)once weekly for 3 weeks in control group” NCT01510535 ↗ |
| Known as | Intragel | “HA formulation will be Intragel (IBSA) which include 2cc with a concentration of 16mg per 2cc.” NCT02258295 ↗ |
| Known as | New Hyaluni | “the group 3 uses 0.15% sodium hyaluronate ophthalmic solution (New Hyaluni 0.15%; Taejoon, Seoul, Korea) 6 times a day.” NCT03640351 ↗ |
| Known as | Oralvisc | “The effects of an oral preparation containing hyaluronic acid (Oralvisc®) on” PMID 24899570 ↗ Jun 2014 |
| Known as | Reviscon Re-Cross | “Participants will receive a single intra-articular injection of high-molecular-weight hyaluronic acid (Reviscon Re-Cross, MV Pharm; 88 mg sodium hyaluronate \[2.2%\] in 4 mL...” NCT07405840 ↗ |
| Known as | sodium hyaluronate/hydroxypropyl guar tear substitute | “a sodium hyaluronate/hydroxypropyl guar tear substitute (Systane Hydration; Alcon, USA)” NCT07812129 ↗ |
| Known as | Systane ultra plus | “The intervention arms will include two commercially available sodium hyaluronate 0.1% (Systane ultra plus and Hylo-comod)” NCT04711642 ↗ |
| Known as | Visco-3 | “Visco-3 (sodium hyaluronate 25 mg/2.5 mL), FDA-approved for knee osteoarthritis.” NCT07688096 ↗ |
| Modality | Other / unclassified | “Hyaluronan 35 kDa (HA35), a glycosaminoglycan polymer, modulates responses to Toll-like receptor 4 (TLR4), a lipopolysaccharide receptor, to improve hepatic and macrophage...” PMID 41494657 ↗ Jan 2026 |
| Route | Other | “eye drops” NCT00938704 ↗ |